Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490193 | 0.91 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL489949 | 0.85 | CXCR2 (0.71) | CXCR2CX3CR1 | |
| SCHEMBL489853 | 0.84 | CXCR2 (0.85) | CXCR2 | |
| SCHEMBL6350808 | 0.81 | CXCR2 (0.68) | CXCR2 | |
| SCHEMBL4080580 | 0.80 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL5497377 | 0.78 | CXCR2 (0.86) | CXCR2CX3CR1 | |
| SCHEMBL6358691 | 0.78 | CXCR2 (0.62) | CXCR2CX3CR1 | |
| SCHEMBL6353801 | 0.77 | CXCR2 (0.65) | CXCR2 | |
| SCHEMBL6351944 | 0.77 | CXCR2 (0.63) | CXCR2 | |
| SCHEMBL6354578 | 0.76 | MGAM (0.51) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958344-B2 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-10-20 | — | — | US | disclosed |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1265899-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001058902-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CCR5, CXCR1, CXCR4 | CXCR2 4/4885CX3CR1 7/4885 |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR2 | CXCR2 3/4885CX3CR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.